Acalabrutinib

Generic Name: Acalabrutinib

Brand Name: Calquence

Manufacturer: AstraZeneca Canada Inc

Therapeutic Area: Chronic Lymphocytic Leukemia (CLL)

Indications: ​As monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy

Manufacturer Requested Reimbursement Criteria¹: As monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.

Submission Type: Initial

Tumour Type: Lymphoma

NOC Status at Filing: Post NOC

Project Status: Complete

Companion Diagnostics: No

Recommendation Type: Reimburse with clinical criteria and/or conditions

Fee Schedule¹: Pending

1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.